Mandy Jackson is a journalist whose work has appeared in Informa. She covers a wide range of topics in the biopharmaceutical industry, including drug development, finance, and industry trends. Mandy's articles provide insights and analysis on the latest news and developments in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Mandy Jackson's coverage focuses on the healthcare and pharmaceutical industry, particularly on drug development, FDA approvals, and biopharmaceutical companies. Additionally, she covers financial aspects related to these sectors.
Given her focus on press releases and private sector announcements, Mandy would likely be responsive to pitches that provide exclusive insights into new drug developments or financial activities within the healthcare and pharmaceutical industries. She may also be interested in expert commentary regarding regulatory changes impacting drug development or financial trends affecting biopharmaceutical companies.
While no specific geographic focus is mentioned for Mandy's coverage area, it’s important to note that her articles cover global developments in the healthcare and pharmaceutical sectors as well as finance-related topics relevant to these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Patients treated with Novo’s PKR activator had a nearly 50% reduction in vaso-occlusive events relative to placebo in Phase II, VOC occurrence was delayed and blood biomarkers improved.
Beam presented data from three more patients than during its last update for BEAM-101, showing stem cell engraftment and efficacy consistent with the first four patients.
By: Mandy Jackson
Hematologists' concerns about hepatoxicity with hemophilia A gene therapies may limit use, but Phase III data for Pfizer's candidate at ASH show a lower rate of ALT increases than seen with BioMarin's Roctavian.
By: Mandy Jackson
Hematologists discussed the still limited treatment options for sickle cell disease at ASH, weighing the risks and benefits of disease-modifying versus curative therapies after the withdrawal of Pfizer's Oxbryta (voxelotor).
Neurocrine will launch Crenessity for adults and children with classic congenital adrenal hyperplasia in less than a week, with pricing available then, adding its second commercial product.
Public Company Edition: Revolution Medicines grossed $862.5m and NewAmsterdam raised $479m in follow-on public offerings, continuing this year’s rise in FOPOs. Janux, CG Oncology, Rocket, ImmunityBio, Protara and Candel also recently raised significant follow-on cash.
By: Mandy Jackson
SiteOne will use its series C venture capital to complete Phase I and initiate Phase II studies for its NaV1.8 inhibitor STC-004 in acute and chronic pain, and to advance other early programs.
Vertex may win US FDA approval in January for the first novel pain drug in decades, after investing a lot of time and inventing new technology to unravel the science behind suzetrigine.
By: Mandy Jackson
The NaV1.8 inhibitor showed a statistically significant change from baseline in lumbosacral radiculopathy pain, but it was the same as the reduction in the study's placebo arm.
Private Company Edition: Ottimo raised $140m-plus in series A venture capital and Angitia garnered $120m in series C cash in the latest mega-rounds, while Noema and Borealis extended prior financings. Also, VC investors XGEN and Dimension raised $690m across two new funds.
(833) 317-6278 
